Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
US FDA approval based on NEURO-TTRansform Phase III results
Development services for gene and cell therapies is planned to begin first in 2025
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
The Government of India continues to prioritise initiatives aimed at enhancing the accessibility and equity of health services
The biopharmaceutical leader shared its expert perspective at the Equality Lounge at the G20 Summit
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Subscribe To Our Newsletter & Stay Updated
